arrow
A

Amy S. Paller

northwestern university
H指数:108
被引数:4.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Insights on Birch Triterpenes in the Treatment of Inherited Epidermolysis Bullosa: Translating Experience to Practice

桦树三萜类化合物在遗传性大疱性表皮松解症治疗中的现实世界见解:将经验转化为实践

2026-09-290
OAAI
Summary of Research: Systemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD Registry

中重度特应性皮炎儿科患者(12岁以下)系统性治疗研究综述:PEDISTAD登记研究中的真实世界治疗结局

2026-04-170
OA
Failed metabolic adaptation to stress contributes to epidermal cell adhesion defects in Darier disease

应激代谢适应失败导致大疱性类天疱疮疾病中表皮细胞粘附缺陷

2026-01-010
OA
Space-related dermatoses

航天相关皮肤病变

2026-01-011
OAAI
Pharmacokinetics and Safety of Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Results of the Real-World Ustekinumab Pediatric Opportunistic Pharmacokinetics Study (U-POPS)

乌司奴单抗在青少年银屑病关节炎患者中的药代动力学和安全性:真实世界乌司奴单抗儿科机会性药代动力学研究(U-POPS)的结果

2025-12-260
OAAI
361 Lebrikizumab Dosed Every 8 Weeks as Maintenance Provides Long-Lasting Response in Patients with Moderate-to-Severe Atopic Dermatitis

361 勒布rikizumab 每8周作为维持剂量使用可为中重度特应性皮炎患者提供长效应答

2025-11-100
PRE
Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of eight clinical trials

特应性皮炎患者中特立洛金单抗的安全性(随访长达4.5年):一项八项临床试验的整合分析

2025-11-011
OAAI